Moderna may be facing regulatory uncertainty in the US for its vaccine pipeline, but at least its clinical data is hitting the right notes.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

Researchers are ushering in a new era of vaccine design that promises to be faster, more precise, and capable of tackling humanity’s most stubborn diseases.

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

REUTERS — The U.S. Centers for Disease Control and Prevention has ended its emergency response for H5N1 avian flu, owing to a decline in animal infections and no reports of human cases since February.

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...

Scientists comment on reports that a child has died in a Liverpool hospital after contracting measles. Prof Sir Andrew Pollard FRCPCH FMedSci FRS, Director of the Oxford Vaccine Group, and Ashall ...

Human organs-on-chips and organoids offer new alternatives to animals for drug development, but there is still a long way to ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="334655" class="cbxwpbkmarktrig ...